Personalized Treatments Hold Promise for Lymphoma Patients
October 15th 2018As lymphoma treatments become less cookie-cutter and more custom, the Leukemia & Lymphoma Society Chief Medical Officer Gwen Nichols, MD, shares how healthcare executives need to alter their approach to managing therapy regimens to increase cure rates and survivorship.
Read More
What Health Execs Need to Know about Tissue-Agnostic Cancer Drug Trials
August 17th 2018Basket trials are designed to test therapies that target a specific genetic mutation found in the tumor, regardless of tumor histology. This emerging trend raises a number of key questions for the industry.
Read More